Windtree Therapeutics (WINT) News Today $0.10 -0.01 (-5.02%) As of 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock WINT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Warrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27 at 4:48 PM | msn.comBNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delistingAugust 20, 2025 | fxstreet.comWindtree Therapeutics Faces Nasdaq Delisting NoticeAugust 20, 2025 | msn.comWindtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest UpdateAugust 20, 2025 | americanbankingnews.comWindtree Therapeutics Delays Q2 2025 Report FilingAugust 14, 2025 | tipranks.comWindtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025August 11, 2025 | globenewswire.comWindtree Therapeutics Terminates SEISMiC-C Clinical StudyAugust 11, 2025 | theglobeandmail.comWindtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study ResultsAugust 7, 2025 | msn.comWindtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy RolloutJuly 30, 2025 | msn.comWindtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and RedemptionJuly 29, 2025 | globenewswire.comWindtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency HoldingsJuly 26, 2025 | msn.comWindtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury StrategyJuly 24, 2025 | globenewswire.comWindtree Shares Soar More Than 100% on BNB Treasury PlansJuly 19, 2025 | msn.comBNB gains 3% following Windtree's plan to launch BNB treasury, H1 reportJuly 16, 2025 | fxstreet.comWindtree to raise $200M to launch a BNB treasury strategyJuly 16, 2025 | msn.comWindtree Therapeutics, Inc. Announces $60 Million Securities Purchase Agreement to Launch BNB Crypto Treasury StrategyJuly 16, 2025 | quiverquant.comQWindtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On SubscriptionsJuly 16, 2025 | globenewswire.comWindtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - NasdaqJuly 4, 2025 | nasdaq.comWindtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart FailureJuly 2, 2025 | globenewswire.comWindtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim AnalysisJune 30, 2025 | finance.yahoo.comWindtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive GelJune 26, 2025 | globenewswire.comWindtree Therapeutics Announces Promising Phase 2 Study Results for IstaroximeJune 17, 2025 | msn.comWindtree Therapeutics Receives $7 Million Offer for Preclinical Oncology PlatformJune 14, 2025 | msn.comWindtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 13, 2025 | finanznachrichten.deWindtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 11, 2025 | tmcnet.comWorking to clean up its finances, Windtree Therapeutics gets into the garbage businessJune 10, 2025 | bizjournals.comWindtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services BusinessJune 10, 2025 | tmcnet.comWindtree Therapeutics to acquire Titan Environmental ServicesJune 10, 2025 | msn.comWINT stock touches 52-week low at $0.75 amid steep annual declineMay 24, 2025 | uk.investing.comWindtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025May 22, 2025 | globenewswire.comWindtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business UpdatesMay 16, 2025 | finanznachrichten.deWindtree Therapeutics announces resale of 42.17M shares by selling stockholdersMay 16, 2025 | msn.comWindtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure CongressMay 13, 2025 | nasdaq.comWindtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025May 12, 2025 | globenewswire.comWindtree Therapeutics Unveils U.S. Exclusivity Strategy for IstaroximeMay 10, 2025 | msn.comWindtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic ShockMay 8, 2025 | nasdaq.comWindtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for USMay 6, 2025 | globenewswire.comWhy biotech firm Windtree Therapeutics is buying a 436-unit apartment complexMay 5, 2025 | bizjournals.comWindtree Therapeutics Announces Plans to Acquire Multifamily Residential PropertyMay 5, 2025 | msn.comWindtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline DevelopmentMay 1, 2025 | finance.yahoo.comWindtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business UpdatesApril 15, 2025 | markets.businessinsider.comEvofem announces license and supply agreement with Windtree TherapeuticsMarch 27, 2025 | markets.businessinsider.comEvofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree TherapeuticsMarch 26, 2025 | prnewswire.comWindtree Therapeutics Regains Compliance with Nasdaq Listing RulesMarch 24, 2025 | globenewswire.comWindtree Therapeutics (NASDAQ:WINT) Stock, Insider Trading ActivityMarch 21, 2025 | benzinga.comWindtree to become sourcing partner for Evofem BiosciencesMarch 21, 2025 | markets.businessinsider.comWindtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI®March 21, 2025 | msn.comAnother Day, Another Biotech Ripping Before The BellMarch 20, 2025 | msn.comWindtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved ProductMarch 20, 2025 | globenewswire.comWINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating CoverageMarch 4, 2025 | msn.com Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WINT Media Mentions By Week WINT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. WINT News Sentiment▼0.521.02▲Average Medical News Sentiment WINT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. WINT Articles This Week▼22▲WINT Articles Average Week Get the Latest News and Ratings for WINT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Windtree Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SCNI News Today VCNX News Today EVFM News Today ZVSA News Today PTPI News Today TNFA News Today BPTH News Today HEPA News Today ORGS News Today VIRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:WINT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access